Foamix has obtained a US Patent for its “Waterless Hydrophilic Foam” for Dermatological and Gynecological Drugs, such as Antibiotics, Antifungals, Corticosteroids, and Drugs for Psoriasis and Atopic Dermatitis.
US Patent No. 8,114,385 , entitled “Oleaginous pharmaceutical and cosmetic foam ” covers a platform of versatile polyethylene glycol-based foam formulations, which can carry a variety of dermatological and gynecological drugs, such as antibiotics, antifungals, corticosteroids, anti-inflammatory, anti-acne and anti-rosacea drugs.
This formulation platform is specifically
The present invention provides stable foam compositions, which comprise primarily hydrophilic carriers, such as Polyethylene glycol. The claims cover the vehicle foam, as well as pharmaceutical compositions that contain at least one active agent for dermal and mucosal delivery. The composition is dispensed as foam providing a stable product that is pleasant and easy to spread, resulting in high patient compliance.
Foamix is the sole company that develops water free dermatological foams.
Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.